Scientific Reports (Mar 2022)

DNA methylation in Friedreich ataxia silences expression of frataxin isoform E

  • Layne N. Rodden,
  • Kaitlyn M. Gilliam,
  • Christina Lam,
  • Teerapat Rojsajjakul,
  • Clementina Mesaros,
  • Chiara Dionisi,
  • Mark Pook,
  • Massimo Pandolfo,
  • David R. Lynch,
  • Ian A. Blair,
  • Sanjay I. Bidichandani

DOI
https://doi.org/10.1038/s41598-022-09002-5
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Epigenetic silencing in Friedreich ataxia (FRDA), induced by an expanded GAA triplet-repeat in intron 1 of the FXN gene, results in deficiency of the mitochondrial protein, frataxin. A lesser known extramitochondrial isoform of frataxin detected in erythrocytes, frataxin-E, is encoded via an alternate transcript (FXN-E) originating in intron 1 that lacks a mitochondrial targeting sequence. We show that FXN-E is deficient in FRDA, including in patient-derived cell lines, iPS-derived proprioceptive neurons, and tissues from a humanized mouse model. In a series of FRDA patients, deficiency of frataxin-E protein correlated with the length of the expanded GAA triplet-repeat, and with repeat-induced DNA hypermethylation that occurs in close proximity to the intronic origin of FXN-E. CRISPR-induced epimodification to mimic DNA hypermethylation seen in FRDA reproduced FXN-E transcriptional deficiency. Deficiency of frataxin E is a consequence of FRDA-specific epigenetic silencing, and therapeutic strategies may need to address this deficiency.